Creating an urgency to change. Mikael Nilsson, Director of Marketing Excellence, Biogen Idec




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Creating an urgency to change. Mikael Nilsson, Director of Marketing Excellence, Biogen Idec
Released on: June 30, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Of the 20 to 60 thousand thoughts we have per day only about 2% are new.
  • Summary
  • Transcript
  • Participants
  • Company
Of the 20 to 60 thousand thoughts we have per day only about 2% are new. Most of our thoughts are old thoughts and that tells us something about the challenge to change. During the eyeforpharma conference in Barcelona Mikael Nilsson, Director of Marketing Excellence at Biogen Idec explained to Fintan Walton how they are managing this process of change using talent within their organisation.
Of the 20 to 60 thousand thoughts we have per day only about 2% are new. Most of our thoughts are old thoughts and that tells us something about the challenge to change. During the eyeforpharma conference in Barcelona Mikael Nilsson, Director of Marketing Excellence at Biogen Idec explained to Fintan Walton how they are managing this process of change using talent within their organisation.
Mikael Nilsson
Biogen Idec
Biogen Idec
Biogen Idec, Inc. is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen Inc. and San Diego, California-based IDEC Pharmaceuticals (formed in 1986 by biotech pioneers Ivor Royston and Howard Birndorf). Biogen, one of the oldest biotechnology companies, was founded in 1978 by several biologists, including Phillip Sharp of the Massachusetts Institute of Technology and Walter Gilbert of Harvard (who served as CEO during the start-up phase).